Skip to content
HCN Grants Est. 2026
No. HT942526BCRPTBCCA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“Invitation to Submit an Application: July 16, 2026” — From the announcement

At a glance

This program funds a highly integrated, multidisciplinary consortium research effort aimed at transforming the lives of people with, or at risk for, breast cancer and accelerating progress toward ending breast cancer. Applicants must be U.S. Department of War organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities; awards are made to organizations, not individuals. The announcement says CDMRP expects to fund about one award with roughly $35 million total cost, with a maximum project period of four years. Cost sharing is not required. The consortium must include at least four and no more than five project teams, at least two institutions, and at least one breast cancer consumer advocate per project team.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide